High response rate but significant toxicity with sequential high-dose ifosfamide (I), carboplatin (C), and etoposide (E) with rituximab for relapsed Hodgkin’s (HD) and large cell non-Hodgkin’s lymphoma (NHL)
| Autor: | Thomas C. Shea, J.S. Serody, Mary Jo Lehman, G. Rey, D. A. Gabriel, Celeste Lindley, Nelson J. Chao, David A. Rizzieri, Jon P. Gockerman |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Ifosfamide business.industry medicine.disease Carboplatin Non-Hodgkin's lymphoma chemistry.chemical_compound Regimen Autologous stem-cell transplantation chemistry Internal medicine medicine Rituximab business Nuclear medicine Etoposide medicine.drug Mesna |
| Zdroj: | Journal of Clinical Oncology. 23:6700-6700 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 6700 Background Ifosfamide, Carboplatin and Etoposide (ICE) are commonly used for the treatment of recurrent HD and NHL prior to autologous stem cell transplantation (ASCT). Since maximizing the single agent dose intensity of each component of a combination regimen has led to improved outcomes in breast cancer, we studied such an approach in lymphoma by developing a regimen in which patients received the dosage equivalents of 3 cycles of combination ICE therapy as sequential single agent treatments. Methods 22 patients (21 evaluable) with relapsed or refractory Hodgkin’s (9) or non-Hodgkin’s Lymphoma (12) received 15 g/m2 I with hydration and mesna, followed by 900 mg/m2 E, followed by C at an AUC of 15 every 21 days. NHL pts received 375 mg/m2 of R with each cycle. Pts received E as the second agent and stem cell apheresis following count recovery prior to receiving C. CR, PR, or SD pts then proceeded to ASCT with CBV (9 pts) or BEAM (6 pts). Prophylactic antibiotics and G-CSF were administered with each... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|